N.B.: This evaluation refers to 2019 and is outdated: display the current evaluation.

NOVARTIS AGCompany logo

Switzerland (CH)

OpenCorporation rating: 52 on 100

Ranking 2019: 146 on 602 companies


Primary NACE classification:
Manufacture of pharmaceutical preparations (2120)

Company description

This company, with headquarters in Basel, Switzerland, is a multinational pharmaceutical company engaged in the research and development of products to protect health, cure disease and improve well-being. The company's prescription drugs include treatments for nervous system and opthalmic disorders, cardiovascular diseases, and cancer. The company is a world leader in pharmaceuticals and consumer health. It was formed in 1996 through the merger of Ciba-Geigy and Sandoz, the two Swiss-based chemical/life sciences giants. The company is organised into four divisions: Pharmaceuticals, which comprises its activities in innovation-driven prescription medicines; Sandoz, which comprises its activities in generic prescription drugs; Consumer health, which comprises activities in OTC, Animal Health, Medical Nutrition, Gerber (formerly Infant & Baby) and CIBA Vision; and Vaccines and Diagnostics, a new division established in April 2006 focusing on the development of preventive treatments and tools. Vaccines and Diagnostics division has two business units formed following the completion of the acquisition of Chiron Corporation: Novartis Vaccines, and Chiron, the blood testing and molecular diagnostics unit. Its consumer health unit includes such brands as Ex-Lax, Maalox, and Theraflu. Other brands include Gerber, Focus, and Sentinel. The company's research is conducted primarily through the Novartis Institutes for BioMedical Research (NIBR). It has strategic alliances with Alnylam, Avalon, Avanir, Broad Institute, Celera, DFCI, GCI, Idera, Infinity, Myogen, Vertex, Biozentrum, Cellzome, and Genedata, and development partners such as Idenix Pharmaceuticals, Emisphere Technologies, SkyePharma, Lohmann, Noven, Biosite, Speedel, Sibia, Ajinomoto, Schering AG, Dainippon, Genentech/Tanox, and Orion. The company aims to discover, develop and successfully market innovative products to treat patients, ease suffering and to enhance the quality of life and seek to provide a return to shareholders that reflects its performance and to adequately reward those who invest ideas and resources in the company.

[…] show more

OpenCorporation questionnaire

The read only version of the questionnaire submitted to this company is publicly available: view questionnaire.

Indicators

The rating is calculated on the following metrics (for more information visit the section Methodology).

score (max is 100)
ratings 2018
56.3
53.3
90.8
90.8
59.5
56.9
34.4
43
51.2
51.2
9.7
9.7
48
48
95.6
45.7

HQ and subsidiaries

NOVARTIS AG
loading subsidiaries

* The position of map pins may not reflect the exact location

About this evaluation

This company did not compile the OpenCorporation questionnaire, for this reason this evaluation was made only on data available to the project staff.

Claims and support from the company

If as a company manager or official of NOVARTIS AG you want to enter in touch with our staff, provide more information to OpenCorporation or get an account to access and compile the company questionnaire, please write an email to support@opencorporation.org.

Tell the OpenCorporation team

If you detect corporate behavior in contrast with what emerges from the OpenCorporation corporate rating card in your country, or in the branch where you work, report it to info@opencorporation.org so that our team can take it in account.

More evaluations

Permament links

The link below will always open the 2019 evaluation:

2019: https://www.opencorporation.org/en/ranking/novartis-ag/2019    url copied

The link below will always open the latest evaluation available:

Last: https://www.opencorporation.org/en/ranking/novartis-ag/last    url copied